activity. Moreover, conditioned media of IFN-y-treated HEL cells accumulated more secreted C1 INH in 8 days (6.7 pg/mL/108 cells) than untreated cells (0.6 I.cglmL/108 cells). Additional studies were done on plasma specimens from 22 patients with metastatic colorectal carcinoma who received IFN-y daily for 4 days by intravenous infusion. Before treatment, the mean 5 SEM C1 INH levels in these patients was 438 k 16 pg/mL. At day 10 from the start of the infusion, the plasma C1 INH in these patients increased to 586 ? 32 pg/mL ( P < .OOOl). The extent of rise of plasma C1 INH after IFN-y treatment was independent of dose from 0.01 to 40 U/m2. After 30 days, the mean plasma C1 INH levels decreased to 502 5 27 pg/mL. These combined studies indicate that IFN-y can increase C1 INH protein expression in vitro and in vivo. 0 1990 by The American Society of Hematology.
affinity chromatography, and gel filtration on sepharose CL-BB, as previously reported.' C1 INH migrated predominantly with an apparent molecular mass of 105 Kd when analyzed by SDS-PAGE under nonreducing conditions. Prekallikrein was purified by the method of Scott et al. 13 Recombinant IFN-7 with specific activity of 1.8 x lo7 U/mg was generously supplied by Genentech, Inc, South San Francisco, CA. Recombinant interferon alpha (IFN-a; 2 x IO8 U/mg) was purchased from Schering Corp, Kenilworth, NJ. Recombinant interferon beta (IFN-b; 5.4 x IO7 U/mg) was provided by Triton Bioscience, Inc, Alameda, CA. Purified a,-macroglobulin was provided by Dr Marc Schapira, Vanderbilt University, Nashville, TN.
The activity of purified C1 INH was measured indirectly by obtaining the pseudo-first order rate constant for the neutralization of purified kallikrein using the chromogenic substrate H-D-Pro-Phe-Arg-pNa, as previously re~0rted.l~ Purified C1 INH antigen was also measured by radial immunodiffusion. ' The CI INH content of washed, solubilized HEL cells and their conditioned media were determined by a competitive enzyme-linked immunosorbent assay (CELISA), done as previously reported using a polyclonal antibody directed to C1 INH. 3 In this assay, purified C1 INH antigen, measured as protein, produced competition inhibition curves that were superimposable onto curves produced by plasma containing equal amounts of C1 INH antigen and plasma from which all detectable C1 INH had been removed by immunoadsorption and then reconstituted with purified C1 INH. 3 The antibodies used in these studies did not show any crossreactivity on immunodiffusion, immunoblot, or CELISA with any preparation of human and bovine serum albumin or fetal bovine serum used in these ~tudies.~.' Antisera to human a,-antitrypsin were provided by Dr Frederick Kueppers, Temple University, Philadelphia, PA. Antigenic a,-antitrypsin was measured in plasma by radial immunodiffusion using pooled normal plasma as the standard of 1 U/mL.'.'' Prekallikrein was measured by means of a spectrophotometric assay using the substrate H-D-Pro-Phe-Arg-pNa, as previously reported."
Functional activity of HEL cell C1 INH. The functional activity of C1 INH in HEL cell lysates was measured by its ability to neutralize the amidolytic activity of purified Only HEL cell lysates whose kallikrein neutralizing activity was 285% neutralized by antibody to C1 INH were used to calculate CI INH functional activity according to the following procedure. To inactivate any possible HEL cell a,-macroglobulin, 48 pL of HEL cell lysate was incubated with 12 pL 0.2 mol/L methylamine, pH 7.4, for 2 hours at 23OC.I4 Preliminary studies showed that this amount of methylamine was sufficient to inhibit an additional 200 pg/mL pure a,-macroglobulin added to an HEL cell lysate. At the time of assay, 10 pL purified kallikrein (1.5 x IO-$ mol/L) were added to the mixture, and at precise intervals (1, 3, 5, 8, 11, 15, 20, 25 , and 35 minutes), 5 pL of the mixture was removed and the residual kallikrein-dependent amidolytic activity was determined as previously reported.I6 The amount of C1 INH activity in the HEL cell lysate was calculated using the integrated second-order reaction
where t is the time of the incubation, k is the second order rate constant for C1 INH inhibition of kallikrein (1.7 x lo4 mol-' s-'),I8 K is the concentration of kallikrein, and K INH is the concentration of kallikrein lost by complexing the C1 INH at each specific time. The amount of C1 INH (INH) was calculated iteratively using a TRS-80 Model 4P computer (Tandy Corp, Fort Worth, TX). When the kallikrein neutralizing activity of HEL cell lysates was not mostly inhibited by antibody to C1 INH, the inhibitor(s)' activity was expressed as the slope of decreasing kallikrein activity over time (0.5 to 8 minutes). The height of the slope correlated with the amount of the inhibitor of kallikrein activity. Chloroform treatment of HEL cell lysates was done as previously reported."' HEL cell culture. HEL cells were obtained from Dr Renato Baserga, Temple University and Dr Lawrence Brass, University of Pennsylvania. The cells were grown in suspension in RPMI 1640 (GIBCO, Grand Island, NY) supplemented with glutamine, antibiotics, and 10% fetal bovine serum (Flow Laboratories, McClean, VA) in a humidified atmosphere with 5% C02. To determine the cellular content of C1 INH and the concentration of HEL cell C1 INH secreted, HEL cells were washed three times by centrifugation with sterile 0.01 mol/L phosphate, 0.15 mol/L NaC1, pH 7.4 (GIBCO). The cells were then resuspended in media that did not contain the dye pH indicator, and were grown for the indicated times. At the end of the incubation, the conditioned media were removed, and the cells were washed five times by centrifugation before being solubilized with 0.5% Triton X-100. To prepare lysates for functional studies, HEL cells were subjected to five freeze-thaw cycles at -7OOC and 37°C in the absence of proteolytic inhibitors. All samples were stored at -7OOC until assay.
Immunoprecipitation of Cl INH from metabolically labeled HEL cells. HEL cell cultures were methionine-starved for 6 hours in RPMI 1640 media containing 10% dialyzed fetal bovine serum and then grown for 48 hours in the presence of [3SS]methionine (125 pCi/mL), in the absence or presence of IFN-y (500 U/mL) according to the procedure of Wohlwend et aI.I9 After labeling, the conditioned media were collected and concentrated by precipitation twice with 60% ammonium sulfate. The precipitate was resuspended into a minimal volume of phosphate-buffered saline and then dialyzed overnight against the same buffer. Immunoprecipitation was done as previously r e p~r t e d .~. '~ Briefly, the concentrated HEL cell conditioned media containing the metabolically labeled proteins were preadsorbed with Pansorbin (staphylococcal protein A; Behring Diagnostics, San Diego, CA) for 30 minutes at 22OC and then incubated overnight at 4OC with a polyclonal antibody to C1 INH3. 4 or with control goat IgG. The next day, Pansorbin was added and the resultant precipitates were washed by centrifugation. The Pansorbin pellets were then incubated with 1 .O mol/L SDS, 2% P-mercaptoethanol in 0.01% Tris, pH 6 to 8, boiled for 5 minutes, and analyzed using 8% SDS-PAGE, according to the procedure of LaemmlL2' The gels were treated with Enhance (Dupont, Wilmington, DE) before drying. Autoradiography was done using Dupont Cronex I1 film with intensifying screens at -8OOC.
Total cellular RNA was prepared from unstimulated HEL cells or HEL cells that had been incubated with IFN-y (1,000 U/mL) for 16 hours using guanidine isothiocyanate and CsCl gradient centrifugation." RNA was quantified by optical density at 260 nm. For Northern blot analysis, total cellular RNA (20 pg) was electrophoresed in 1% agarose-formaldehyde gels and transferred onto nitrocellulose filters.22
A cDNA probe to human C1 INH was provided by Dr Susan C.
Bock, Temple University, Philadelphia, PA.Z3 A mixture of a 0.5 and 1.3 kb fragments derived from this plasmid cDNA by a double digest using EcoRI and HindIII.ZJ A 0.7 kb HindRIII and BamHI fragment of actin-y cDNAZ4 was used as a probe for the quantity of total RNA added to the gel. A cDNA probe to plasminogen activator inhibitor 1 was provided by Dr T-C Wun, Monsanto Chemical Corp, St Louis, MO." All these probes were radiolabeled with ["PIdCTP by the random primer technique.26 Studies for protease nexin I mRNA were done by D. Guttridge, University of California at Irvine, Irvine, CA, using a 603 bp ['2P]-radiolabeled riboprobe produced from a cDNA corresponding to amino acids 150 to 350." Hybridization was carried out overnight in 6X SSC, 0.1% SDS, and 1OX Denhardt's solution containing 200 pg/mL salmon sperm DNA at 42°C. After hybridization, the filters with C1 INH and plasminogen activator inhibitor I probes were washed twice with 2X SSC, 0.1% SDS; twice with 1X SSC, 0.1% SDS; and once with 0.1X SSC, 0.1% SDS; all at 42°C for 30 minutes each. The filters with the actin-y probe were washed once with 2X SSC, 0.1% SDS followed by 0.1X SSC, 0.1% SDS, both at 65OC. The filters were then exposed to Dupont Cronex I1 film with intensifying screens at -8OOC.
Plasma samples were collected in 3.8 g % sodium citrate (1 part anticoagulant to 9 parts blood) from 22 patients with metastatic colorectal carcinoma who were enrolled in Phase 1 trials to assess the toxicity and efficacy of IFN-y for treatment of their malignancy. Most of these patients were either asymptomatic or mildly symptomatic.,' All of these patients gave full written informed consent before entering the study. The patients were treated with variable doses of IFN-y (0.001 to 60 x 10' U/m') intravenously by 4-hour infusions daily for 4 consecutive days. Plasma samples were collected before therapy and on day 10 and 30 after therapy was started. Only patients who contributed plasma RNA isolation and Northern blot analysis.
Patient studies.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From specimens on all 3 days were included in the analysis. The data were analyted by grouped paired t test.
RESULTS
Initial investigations determined that HEL cells constitutively expressed the 2.1 kb mRNA for CI INH (Fig I) . When HELcells werestimulated with IFN-y (1,000 U/mL) for 16 hours, theamount ofmRNA for CI INH incrcascd. In contrast. equal amounts of actin-y mRNA were expressed by unstimulatcd and I FN-y-stimulated cells. I FN-y specifically increased CI INH mRNA expression. Neither IFN-a nor -0 were able to obviously elevate HEL cell CI INH mRNA expression (data not shown). However. the extent of elevation of HEL cell CI INH mRNA exprcssion by IFN-y was only about twofold greater than unstimulated cells after treatment of the HEL cells with 50 to 1,000 U/mL IFN-y (data not shown).
Further investigations were done to determine if IFN-y could modulate C1 INH protein expression in HEL cells. IFN-y increased the concentration o f C 1 INH expressed within HEL cells (Fig 2A) . Unstimulated HEL cells contained 1. The CI INH immunoprecipitated from the conditioned media of metabolically labeled HEL cells was 105 Kd (Fig  3) . When the same number of cells were treated with IFN-y. the amount of immunoprecipitable. metabolically labeled C 1 I N H increased. The IFN-y-stimulated HEL cell induction of CI I N H produced a functionally active form of the Table 2) . Alternatively, 84%. of the kallikrein neutralizing activity of unstimulated HEL cells lysates. similar to the kallikrein neutralizing activity of IFN-y-treated cells (data not shown), was eliminated by treatment of the material with chloroform. The specific protease inhibitor that accounted for the kallikrein neutralizing activity in unstimulated HEL cells was not identified. The kallikrein neutralizing activity of lysates from unstimulated HEL cells was the same. regardless of whether or not the lysate was treated with methylamine. Moreover. neither plasminogen activator inhibitor 1 nor protease ncxin I mRNA were found in unstimulated or IFN-y-treated total RNA from HEL cells.
Additional studies were done to determine if IFN-y could increase plasma CI INH levels in vivo. Plasma samplcs from 22 patients with metastatic colorectal carcinoma who had received IFN-y as part of Phase 1 trials were studied for CI INH antigen (Fig 4A) . Before the infusion, the mean t SEM CI INH level in these patients was 438 2 16 pg/mL.
At day IO after the start of the administration of the IFN-y, the plasma CI INH level in these patients increased to 586 2 32 pg/mL (P e .OOOl) After 30 days from the start of the infusion, the mean plasma CI INH levels in these patients decreased to 502 2 27 pg/mL ( P < .01 when compared with day IO: P > . I when compared with day 0). Even though there was a wide range of doses of IFN-y used to treat these patients, there was no relation between the size of the dose of IFN-y and the extent of elevation of the patient's plasma CI INH level (Fig 48) . The rise in these patients'cl INH levels after IFN-y treatment was not just due to the course of their illness. Their a,-antitrypsin levels, although the baseline was also elevated over normals, remained stable at 2. present in platelets. endothelial cells. and m~nocytes.'~~'.* and because this cell line expresses many features characteristic of megakaryocytes and m0"cytes.'"'' The ability of IFN-y to increase the protein expression of CI INH in HEL cells is consistent with previous studies with endothelial cells. monocytes. synovial fibroblasts, and skin fibroblasts (Figs 2  and 3) .r.".9.29.'" In addition to increasing CI INH protein production. IFN-y has also been recently described to For U/mL IFNy. After washing by centrifugation five times in 0.01 mol/L sodium phosphate, 0.15 mol/L NaCI, pH 7.4, containing 0.2% bovine serum albumin, the final pellet was resuspended at 10' cells/mL. The cell suspension was frozen at -70°C and thawed at 37°C five times, and the 10,OOOg supernatant was obtained.
.The kallikrein neutralizing activity of the HEL cell lysate was determined by noting the decrease in the rate of hydrolysis of the chromogenic substrate at precise time intervals (0.5. increase the molecular expression of C1 INH mRNA in human skin fibroblasts, monocytes, and endothelial The present study expands the list of cell lines that produce CI INH and that are responsive to IFN-y. Within 16 hours of IFN-y treatment, there was a distinct increase in the mRNA coding for CI INH (Fig 1) . This increase in C1 INH message in the HEL cells produced a significant increase in the concentration of synthesized CI INH secreted into the conditioned media after only 4 days of continuous IFN-y treatment (Figs 2 and 3) .
The IO-fold increase after IFN-y treatment in the concentration of CI INH at 8 days in both the HEL cell lysate and its conditioned media over unstimulated control material suggest that this cell line could be used to produce large in vitro quantities of CI INH for replacement therapy. This idea is enhanced by the finding that the CI INH produced by the HEL cells is the same size (105 Kd) as normal plasma CI INH (Fig 3) . This finding suggests that the HEL cell C1 INH may have a similar glycosylation as normal plasma C1 INH. Further, the HEL cell CI INH from IFN-y-treated cells retained its functional ability to neutralize kallikrein ( Table I) . At day 4 of IFN-y treatment, the concentration of CI INH activity (15 pg/mL) was similar to the concentration of CI INH antigen (19 pg/mL) measured in the HEL cell lysate. We were surprised to find so much kallikrein neutralizing activity also in lysates of unstimulated HEL cells ( Table 2 ). The fact that antibody to C1 INH did not block the kallikrein neutralizing activity of unstimulated HEL cell lysates suggested that there was another kallikrein inhibitor(s) in unstimulated HEL cells lysates. This inhibitor(s) was downregulated by IFN-y while CI INH expression in the same cells was being upregulated. The fact that methylamine did not neutralize the kallikrein inhibitor in unstimulated HEL cells indicates that it was not 02-macr~globulin.'~ The lack of evidence for plasminogen activator inhibitor 1 or protease nexin I mRNA in 20 pg of unstimulated HEL cell total RNA suggests that these two other recognized kallikrein inhibitors are also not accounting for this However, the finding that chloroform almost completely neutralized the kallikrein inhibiting activity of the HEL cell lysate suggests that the inhibitor may have structural similarity to CI INH." (Fig 4A) . The rise in these patients' C1 INH levels was not just due to their illness, because their a,-antitrypsin levels were not elevated after treatment. The degree of C1 INH elevation is striking for two reasons: IFN-y was able to elevate C1 INH levels 150 pg/mL above levels that were already high, and the C I INH values were elevated for at least 6 days after the completion of the infusion of IFN-y. The high level of CI INH in these patients before the infusion is characteristic of this protein being an acute phase r e a~t a n t .~' The concomitant finding that a,-antitrypsin was also elevated supports this assessment. Although we are cautious in extrapolating the results of clinical data from cancer patients to individuals with hereditary angioedema, an increase in C1 INH levels of 150 pg/mL or 34% over pretreatment values after completion of an IFN-y infusion may ameliorate clinical symptoms associated with C1 INH deficiency.
Although IFN-y infusion may be associated with many side effects,38 there was no relation between the doses of IFN-y infused and the extent of rise in patient plasma CI INH levels (Fig 4B) . Therefore, very small doses of IFN-y, below the level that may induce side effects, may be sufficient to modulate an increase in the production of CI INH in vivo. IFN-y exhibits a bell-shaped, dose-biologic response curve in its potentiation of human monocyte lysis of allogeneic tumor cells.38 Similar relationships have been seen with class I1 antigen expression, Fc receptor expression, and monocyte hydrogen peroxide prod~ction.~' Further studies are needed to determine if low dose IFN-y therapy can increase plasma C1 INH levels in some patients with hereditary angioedema and to determine if this increase in the level of C1 INH can ameliorate acute exacerbations of this disorder.
